Literature DB >> 28004221

Overexpression of teneurin transmembrane protein 1 is a potential marker of disease progression in papillary thyroid carcinoma.

Shih-Ping Cheng1,2, Ming-Jen Chen1,3,2, Ming-Nan Chien4, Chi-Hsin Lin3, Jie-Jen Lee1,2, Chien-Liang Liu5.   

Abstract

Although papillary thyroid cancer is a relatively indolent malignancy, its progression may be associated with dedifferentiation and resistance to radioactive iodine treatment. In this study, patterns of differentially expressed genes in association with disease progression were systemically evaluated. We firstly performed transcriptome analyses for four matched cancerous and noncancerous tissue pairs of the classical subtype of papillary thyroid cancer. Among the upregulated and downregulated genes, the expression of 164 and 183 genes increased and decreased, respectively, from stage I to stage IV. Functional enrichment and pathway analysis showed that angiogenesis pathway was upregulated, whereas oxidation-reduction and metabolism of reactive oxygen species were downregulated. Teneurin transmembrane protein 1 (TENM1) expression was highly upregulated in cancerous tissues and negative in benign thyroid tissues. By immunohistochemistry, TENM1 expression in papillary thyroid cancer was associated with the classical subtype (p = 0.018), extrathyroidal invasion (p = 0.001), BRAF V600E mutation (p < 0.001), and an advanced stage (p = 0.019). Taken together, our results indicate that distinct pathways are involved in papillary thyroid cancer progression, and TENM1 is a potential marker of cancer progression.

Entities:  

Keywords:  Disease progression; Next-generation sequencing; Papillary thyroid cancer; RNA-Seq; TENM1

Mesh:

Substances:

Year:  2016        PMID: 28004221     DOI: 10.1007/s10238-016-0445-y

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  34 in total

1.  SOAP2: an improved ultrafast tool for short read alignment.

Authors:  Ruiqiang Li; Chang Yu; Yingrui Li; Tak-Wah Lam; Siu-Ming Yiu; Karsten Kristiansen; Jun Wang
Journal:  Bioinformatics       Date:  2009-06-03       Impact factor: 6.937

2.  Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V600E expression in thyroid cancer.

Authors:  Tao-Yeuan Wang; Chien-Liang Liu; Ming-Jen Chen; Jie-Jen Lee; Pou Chu Pun; Shih-Ping Cheng
Journal:  Histopathology       Date:  2014-11-25       Impact factor: 5.087

Review 3.  Angiogenesis in benign and malignant thyroid disease.

Authors:  Jamie C Mitchell; Sareh Parangi
Journal:  Thyroid       Date:  2005-06       Impact factor: 6.568

4.  Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information.

Authors:  C Montero-Conde; J M Martín-Campos; E Lerma; G Gimenez; J L Martínez-Guitarte; N Combalía; D Montaner; X Matías-Guiu; J Dopazo; A de Leiva; M Robledo; D Mauricio
Journal:  Oncogene       Date:  2007-09-17       Impact factor: 9.867

Review 5.  Teneurin protein family: an emerging role in human tumorigenesis and drug resistance.

Authors:  Annemarie Ziegler; Alejandro Corvalán; Iván Roa; Jorge A Brañes; Bernd Wollscheid
Journal:  Cancer Lett       Date:  2012-07-24       Impact factor: 8.679

6.  RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.

Authors:  Robert C Smallridge; Ana-Maria Chindris; Yan W Asmann; John D Casler; Daniel J Serie; Honey V Reddi; Kendall W Cradic; Michael Rivera; Stefan K Grebe; Brian M Necela; Norman L Eberhardt; Jennifer M Carr; Bryan McIver; John A Copland; E Aubrey Thompson
Journal:  J Clin Endocrinol Metab       Date:  2013-12-02       Impact factor: 5.958

7.  Discrimination of benign and malignant thyroid nodules by molecular profiling.

Authors:  David J Finley; Baixin Zhu; Catherine B Barden; Thomas J Fahey
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

8.  Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.

Authors:  Linwah Yip; Marina N Nikiforova; Jenny Y Yoo; Kelly L McCoy; Michael T Stang; Michaele J Armstrong; Kristina J Nicholson; N Paul Ohori; Christopher Coyne; Steven P Hodak; Robert L Ferris; Shane O LeBeau; Yuri E Nikiforov; Sally E Carty
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

Review 9.  Classification of follicular cell-derived thyroid cancer by global RNA profiling.

Authors:  Maria Rossing
Journal:  J Mol Endocrinol       Date:  2013-03-18       Impact factor: 5.098

10.  Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas.

Authors:  J M Pita; A Banito; B M Cavaco; V Leite
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more
  12 in total

1.  Heterogenous nature of gene expression patterns in BRAF-like papillary thyroid carcinomas with BRAFV600E.

Authors:  Yuji Nagayama; Hiroyuki Mishima
Journal:  Endocrine       Date:  2019-09-02       Impact factor: 3.633

2.  Expression of serine peptidase inhibitor Kunitz type 1 in differentiated thyroid cancer.

Authors:  Chien-Liang Liu; Po-Sheng Yang; Ming-Nan Chien; Yuan-Ching Chang; Chi-Hsin Lin; Shih-Ping Cheng
Journal:  Histochem Cell Biol       Date:  2018-03-12       Impact factor: 4.304

3.  Overexpression of Histone H3 Lysine 27 Trimethylation Is Associated with Aggressiveness and Dedifferentiation of Thyroid Cancer.

Authors:  Chia-Chi Tsai; Ming-Nan Chien; Yuan-Ching Chang; Jie-Jen Lee; Shuen-Han Dai; Shih-Ping Cheng
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

4.  Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.

Authors:  Rebecca Graumann; Gabriella A Di Capua; Juan E Oyarzún; Marcos A Vásquez; Christine Liao; Jorge A Brañes; Iván Roa; Paola Casanello; Alejandro H Corvalán; Gareth I Owen; Iris Delgado; Uwe Zangemeister-Wittke; Annemarie Ziegler
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

5.  Loss of Integrase Interactor 1 (INI1) Expression in a Subset of Differentiated Thyroid Cancer.

Authors:  Kung-Chen Ho; Jie-Jen Lee; Chi-Hsin Lin; Ching-Hsiang Leung; Shih-Ping Cheng
Journal:  Diagnostics (Basel)       Date:  2020-05-05

Review 6.  Teneurins: Role in Cancer and Potential Role as Diagnostic Biomarkers and Targets for Therapy.

Authors:  Giulia Peppino; Roberto Ruiu; Maddalena Arigoni; Federica Riccardo; Antonella Iacoviello; Giuseppina Barutello; Elena Quaglino
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

7.  Heme Oxygenase-1 Inhibitors Induce Cell Cycle Arrest and Suppress Tumor Growth in Thyroid Cancer Cells.

Authors:  Po-Sheng Yang; Yi-Chiung Hsu; Jie-Jen Lee; Ming-Jen Chen; Shih-Yuan Huang; Shih-Ping Cheng
Journal:  Int J Mol Sci       Date:  2018-08-24       Impact factor: 5.923

8.  Long non-coding RNA, LINC01614 as a potential biomarker for prognostic prediction in breast cancer.

Authors:  Yaozong Wang; Baorong Song; Leilei Zhu; Xia Zhang
Journal:  PeerJ       Date:  2019-11-14       Impact factor: 2.984

9.  Quinolinate Phosphoribosyltransferase Promotes Invasiveness of Breast Cancer Through Myosin Light Chain Phosphorylation.

Authors:  Chien-Liang Liu; Shih-Ping Cheng; Ming-Jen Chen; Chi-Hsin Lin; Shan-Na Chen; Yi-Hue Kuo; Yuan-Ching Chang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-04       Impact factor: 5.555

10.  A Five-Gene Prognostic Nomogram Predicting Disease-Free Survival of Differentiated Thyroid Cancer.

Authors:  Pan Ruchong; Tang Haiping; Wang Xiang
Journal:  Dis Markers       Date:  2021-06-15       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.